Vis enkel innførsel

dc.contributor.authorYanes, Manar
dc.contributor.authorGiola, Santoni
dc.contributor.authorMaret-Ouda, John
dc.contributor.authorNess-Jensen, Eivind
dc.contributor.authorFärkkilä, Martti
dc.contributor.authorLynge, Elsebeth
dc.contributor.authorNwaru, Bright I.
dc.contributor.authorPukkala, Eero
dc.contributor.authorRomundstad, Pål Richard
dc.contributor.authorTryggvadóttir, Laufey
dc.contributor.authorvon Euler-Chelpin, My
dc.contributor.authorLagergren, Jesper
dc.date.accessioned2021-03-03T12:49:01Z
dc.date.available2021-03-03T12:49:01Z
dc.date.created2021-01-18T15:31:53Z
dc.date.issued2020
dc.identifier.citationEuropean Journal of Cancer. 2020, 138 80-88.en_US
dc.identifier.issn0959-8049
dc.identifier.urihttps://hdl.handle.net/11250/2731436
dc.description.abstractIntroduction Airway micro-aspiration might contribute to the proposed associations between gastroesophageal reflux disease (GERD) and some lung diseases, including lung cancer. This study aimed to examine the hypothesis that antireflux surgery decreases the risk of small cell carcinoma, squamous cell carcinoma and adenocarcinoma of the lung differently depending on their location in relation to micro-aspiration. Methods Population-based cohort study including patients having undergone antireflux surgery during 1980–2014 in Denmark, Finland, Iceland, Norway or Sweden. Patients having undergone antireflux surgery were compared with two groups: 1) the corresponding background population, by calculating standardised incidence ratios (SIRs) with 95% confidence intervals (CIs) and 2) non-operated GERD-patients, by calculating hazard ratios (HRs) with 95% CIs using multivariable Cox regression with adjustment for sex, age, calendar period, country, chronic obstructive pulmonary disease and obesity diagnosis or type 2 diabetes. Results Among all 812,617 GERD-patients, 46,996 (5.8%) had undergone antireflux surgery. The SIRs were statistically significantly decreased for small cell carcinoma (SIR = 0.57, 95% CI 0.41–0.77) and squamous cell carcinoma (SIR = 0.75, 95% CI 0.60–0.92), but not for adenocarcinoma of the lung (SIR = 0.90, 95% CI 0.76–1.06). The HRs were also below unity for small cell carcinoma (HR = 0.63, 95% CI 0.44–0.90) and squamous cell carcinoma (HR = 0.80, 95% CI 0.62–1.03), but not for adenocarcinoma of the lung (HR = 1.03, 95% CI 0.84–1.26). Analyses restricted to patients with objective GERD (reflux oesophagitis or Barrett's oesophagus) showed similar results. Conclusions This all-Nordic study indicates that patients who undergo antireflux surgery are at decreased risk of small cell carcinoma and squamous cell carcinoma of the lung, but not of adenocarcinoma of the lung.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleAntireflux surgery and risk of lung cancer by histological type in a multinational cohort studyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber80-88en_US
dc.source.volume138en_US
dc.source.journalEuropean Journal of Canceren_US
dc.identifier.doi10.1016/j.ejca.2020.07.018
dc.identifier.cristin1873445
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode2


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal